CJC-1295 (No DAC) Product Brief

Ready-to-Sell Research Product Sheet

1. Compound Overview

CJC-1295 (No DAC), also referred to as Modified GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH).
Unlike CJC-1295 with DAC, the no-DAC version has a shorter half-life and is designed to mimic the body’s natural pulsatile growth hormone release patterns.

It is commonly studied in research exploring growth hormone signaling, metabolism, recovery pathways, and body composition regulation.

2. Mechanism of Interest

CJC-1295 (No DAC) is studied for several biological mechanisms:

• Activation of the GHRH receptor
  • Stimulation of endogenous growth hormone release
  • Support of pulsatile GH secretion patterns
  • Potential increase in IGF-1 signaling pathways
  • Influence on metabolic and recovery-related pathways

3. Research Areas Being Explored

• Growth hormone pulsation research
  • Body composition studies
  • Recovery and regeneration pathways
  • Sleep quality research models
  • Metabolic signaling studies

4. Suggested Research Vial Sizes

• 2 mg lyophilized vial
  • 5 mg lyophilized vial
  • 10 mg research vial

5. Example Reconstitution Chart

Example mixing protocols commonly used in research contexts:

2 mg vial + 1 mL bacteriostatic water = 2 mg/mL concentration

5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL concentration

10 mg vial + 2 mL bacteriostatic water = 5 mg/mL concentration

These concentrations allow accurate measurement using insulin syringes for laboratory research settings.

6. Label Information for Vials

• Compound name: CJC-1295 (No DAC)
  • Total amount per vial (mg)
  • Lot / batch number
  • Manufacturing date
  • Storage instructions (2–8°C recommended)
  • Research use only disclaimer

7. Market Positioning

CJC-1295 (No DAC) is commonly positioned in the growth hormone research peptide category.

It is frequently marketed for research involving:

• Growth hormone pulsation models
  • Recovery and regenerative studies
  • Body composition research
  • Metabolic and endocrine signaling pathways

8. Example Research Stack Categories

• CJC-1295 (No DAC) + Ipamorelin
  • CJC-1295 (No DAC) + BPC-157
  • CJC-1295 (No DAC) + TB-500
  • CJC-1295 (No DAC) + IGF-1 related research peptides

9. Safety and Regulatory Notes

CJC-1295 (No DAC) is not approved by the FDA for medical treatment and is commonly distributed as a research compound.

This document is intended for informational and research product description purposes only.